Candel Therapeutics will present new SITC data on aglatimagene besadenovec in non-small cell lung cancer and linoserpaturev in glioblastoma, extending its immune-activation oncology strategy after earlier prostate cancer results.
published
Candel Therapeutics will present new SITC data on aglatimagene besadenovec in non-small cell lung cancer and linoserpaturev in glioblastoma, extending its immune-activation oncology strategy after earlier prostate cancer results.
Latest documented BWB result
BWB member result
Exit /ES with a huge win - 56 Points or 224 ticks
Historical results are not a promise of future performance. Trading involves substantial risk.This public post is a timestamped information archive, not personalized financial advice. Alerts can change as markets move. Join Billy's private group for the complete daily stream and follow-through.